This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n7http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11130%2F14%3A10292954%21RIV15-MSM-11130___/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11130%2F14%3A10292954%21RIV15-MSM-11130___
rdf:type
skos:Concept n17:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1089/dia.2013.0302
dcterms:description
Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence suggesting that structured SMBG is beneficial for all type 2 diabetes patients, regardless of therapy. However, access to SMBG can be limited in many countries in Central and Eastern Europe. A consensus group of diabetes experts from 10 countries in this region (with overlapping historical, political, and social environments)-Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia, and Ukraine-was formed to discuss the role of SMBG across the spectrum of patients with diabetes. The group considered SMBG to be an essential tool that should be accessible to all patients with diabetes, including those with non-insulin-treated type 2 diabetes. The current article summarizes the evidence put forward by the consensus group and provides their recommendations for the appropriate use of SMBG as part of individualized patient management. The ultimate goal of these evidence-based recommendations is to help patients and providers in Central and Eastern Europe to make optimal use of SMBG in order to maximize the efficacy and safety of glucose-lowering therapies, to prevent complications, and to empower the patient to play a more active role in the management of their diabetes. Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence suggesting that structured SMBG is beneficial for all type 2 diabetes patients, regardless of therapy. However, access to SMBG can be limited in many countries in Central and Eastern Europe. A consensus group of diabetes experts from 10 countries in this region (with overlapping historical, political, and social environments)-Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia, and Ukraine-was formed to discuss the role of SMBG across the spectrum of patients with diabetes. The group considered SMBG to be an essential tool that should be accessible to all patients with diabetes, including those with non-insulin-treated type 2 diabetes. The current article summarizes the evidence put forward by the consensus group and provides their recommendations for the appropriate use of SMBG as part of individualized patient management. The ultimate goal of these evidence-based recommendations is to help patients and providers in Central and Eastern Europe to make optimal use of SMBG in order to maximize the efficacy and safety of glucose-lowering therapies, to prevent complications, and to empower the patient to play a more active role in the management of their diabetes.
dcterms:title
Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe-Recommendations from the International Central-Eastern European Expert Group Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe-Recommendations from the International Central-Eastern European Expert Group
skos:prefLabel
Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe-Recommendations from the International Central-Eastern European Expert Group Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe-Recommendations from the International Central-Eastern European Expert Group
skos:notation
RIV/00216208:11130/14:10292954!RIV15-MSM-11130___
n3:aktivita
n11:V
n3:aktivity
V
n3:cisloPeriodika
7
n3:dodaniDat
n14:2015
n3:domaciTvurceVysledku
n4:2117371 n4:5479851
n3:druhVysledku
n5:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
44335
n3:idVysledku
RIV/00216208:11130/14:10292954
n3:jazykVysledku
n19:eng
n3:klicovaSlova
management; mellitus; insulin; parallel-group; glucometabolic control; randomized-trial; metabolic-control; quality-of-life; improves glycemic control; rosso-in-praxi
n3:klicoveSlovo
n10:improves%20glycemic%20control n10:metabolic-control n10:mellitus n10:randomized-trial n10:rosso-in-praxi n10:parallel-group n10:quality-of-life n10:insulin n10:management n10:glucometabolic%20control
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[86C997C1D3C3]
n3:nazevZdroje
Diabetes Technology and Therapeutics
n3:obor
n6:FB
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
17
n3:rokUplatneniVysledku
n14:2014
n3:svazekPeriodika
16
n3:tvurceVysledku
Czupryniak, Leszek Tankova, Tsvetalina Roman, Gabriela Varkonyi, Tamas Brož, Jan Zherdova, Nadia Krnic, Mladen Martinka, Emil Bronisz, Agata Wolnik, Bogumil Janez, Andrej Bolgarska, Svetlana Lalic, Nebojsa Barkai, Laszlo Rahelic, Dario Honka, Marek Cypryk, Katarzyna
n3:wos
000338186100009
s:issn
1520-9156
s:numberOfPages
16
n7:doi
10.1089/dia.2013.0302
n16:organizacniJednotka
11130